Aeterna Zentaris to Distribute Armune’s Apifiny Test in the U.S.

Aeterna Zentaris has secured a co-marketing agreement with Kalamazoo, Mich.-based Armune BioScience to distribute Apifiny, a non-PSA blood test for the detection of prostate cancer.

Under the agreement, Aeterna Zentaris will distribute the test in U.S. territories and receive a commission for each test performed resulting from the promotion. Additional financial terms were not disclosed.

Armune’s Apifiny is based on the measurement of eight prostate cancer-specific autoantibodies in human serum, which are produced and amplified by the immune system in the presence of prostate cancer cells. — Michael Cipriano